×

Register now for access to the Parexel Biotech Content Hub

First Name
Last Name
Company Name
Job Title
Country
Thank you!
Error - something went wrong!
   

Strengthen Your Product Value Story One Phase at a Time

August 23, 2017

Addressing evidence generation in a phase-specific manner provides mutually reinforcing benefits: trials contribute to the value argument and the value data inform the design of the trials. In this way, utilizing the best available secondary research to inform primary research can reduce the risk of regulatory and reimbursement rejections.

A phase-dependent approach has potential to cut costs by avoiding investing in riskier assets, utilizing secondary evidence for multiple assets (thereby using resources more efficiently), and creating payer value while simultaneously meeting regulatory requirements.

The best way to plan evidence generation for the value story is from the beginning. But if you didn’t do that already, the sooner you start the better.

 

Previous Flipbook
Plan & Engage Early to Manage the Risks of Risk Management
Plan & Engage Early to Manage the Risks of Risk Management

Next Flipbook
Using real-world evidence to help your product succeed
Using real-world evidence to help your product succeed

Let us show you how our experience of leveraging real-world data (RWD) and real-world evidence (RWE) can he...

×

Speak to a Parexel® Biotech expert today!

First Name
Last Name
Job Title
Company Name
Country
Tell us how we can help
Thank you!
Error - something went wrong!